Strategies for detecting pharmacotherapeutic and educational needs of patients with cardiovascular risk in community pharmacy
DOI:
https://doi.org/10.30827/ars.v64i3.27735Keywords:
Community Pharmacy, Cardiovascular Risk, Educational Needs, Professional Pharmaceutical ServicesAbstract
Introduction: Cardiovascular diseases are the leading cause of mortality, and community pharmacy (CP) can help patients improve modifiable cardiovascular risk factors (CVRF): hypertension (HT), dyslipidaemia, diabetes mellitus (DM), smoking, and obesity. Professional pharmaceutical services related to community health include this type of action. The aim of this study was to determine the socio-health and pharmacotherapeutic profile of patients with CVR treated in Spanish CP, to design the most effective intervention for them.
Method: A descriptive cross-sectional study was conducted between January 2017 and February 2018. Using a data collection form, data from patients in four CP, two in Seville and two in Badajoz (Spain) were recorded through individualised interviews.
Results: The initial sample (n=100) was reduced to 98 patients, older (61.5±10.1 years), 51.0 % male, with low educational level (53.1 %) and most of them living accompanied (87.8 %). 74.5 % were patients in primary prevention and their CVR level was moderate (2.51±1.89). Hypertension (83.7 %), dyslipidaemia (64.39 %), diabetes II (38.8 %) and obesity (52.0 %) were the most prevalent factors. Almost half of the patients (48.5 %) exercised regularly and 23.5 % were smokers. The drugs most commonly used were lipid modifiers (59.4 %), oral antidiabetics (37.5 %), antithrombotics (32.2 %) and beta-blockers (28.1 %).
Conclusions: The use of forms aimed at detecting the educational and pharmacotherapeutic needs of CVR patients will allow one to establish different strategies to improve their ability to manage their disease.
Downloads
References
World Health Organitation (WHO). Technical package for cardiovascular disease management in primary health care. Ediciones de la OMS [Internet]. 2016 Junio [citado Junio 2022]. 73p. Disponible en: https://apps.who.int/iris/bitstream/handle/10665/252661
Instituto Nacional de Estadística (INE). Defunciones según la causa de muerte [Internet]. 2022 Noviembre [citado Noviembre 2022]. 16 p. Disponible enhttps://www.ine.es/prensa/edcm_2021.pdf
Celentano A, Panico S, Palmieri V, Guillaro B, Brancati C, di Palma Esposito N. Citizens and family doctors facing awareness and management of traditional cardiovascular risk factors: results from the Global Cardiovascular Risk Reduction Project (Help Your Heart Stay Young Study). NutrMetabCardiovascDis. 2003;13:211–7.DOI: 10.1016/s0939-4753(03)80013-3
Frijling BD, Lobo CM, Keus IM, Jenks KM, Akkermans RP, Hulscher ME. Perceptions of cardiovascular risk among patients with hypertension or diabetes. Patient EducCouns. 2004;52:47–53. DOI: 10.1016/s0738-3991(02)00248-3
Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. EurHeart J. 2007;28(19):2375-2414.
Foro de Atención Farmacéutica en farmacia Comunitaria (Foro de AF-FC). Quinto Comunicado. Cartera de Serviciuos Farmacéuticos en la Farmacia Comunitaria.PharmCare Es. 2012; 14(1):31-32
Foro de AF-FC. Servicios Profesionales Farmacéuticos Asistenciales. Madrid; 2016. 4p.
Martín-Calero MJ, de la Matta MJ, Marín F, Lorenzo R, Luís AM, Villegas I. La caracterización de pacientes como herramienta útil para ofrecer servicios personalizados en farmacia comunitaria. Farmacéuticos Comunitarios. 2015;7(4):5-17.
Fliefel R, Tröltzsch M, Kühnisch J, Ehrenfeld M, Otto S. Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. Int J Oral MaxiliofacSurg. 2015;44(5):568-85. DOI: 10.1016/j.ijom.2015.01.026.
Modelo de coordinación médico-farmacéutico para la atención al paciente con enfermedad crónica en atención primaria. https://www.semg.es/images/documentos/2017/documentos/Coordinacion_medico_farmaciutica.pdf
Williams B, Mancia G, Spiering W, AgabitiRosei E, Azizi M, Burnier M, et al. Guía ESC/ESH 2018 sobre el diagnóstico y tratamiento de la hipertensión arterial. Rev EspCardiol. 2019;72(2):160.e1- e78.
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111-88.
Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, et al. American Association of Clinical Endocrinologists and American College of Endocrinology- Clinical practice guidelines for developing a diabetes mellitus comprehensive care plan-2015. EndocrPract. 2015;21 suppl1:1-87.
Sociedad Española para el Estudio de la Obesidad (SEEDO) [Internet]. 2022 Noviembre [citado Noviembre 2022]. Disponible en: https://www.seedo.es/index.php/pacientes/calculo-imc.
WHO. WHO Guidelines on physical activity and sedentary behaviour. Ediciones de la OMS [Internet]. 2022 Noviembre. [citado Noviembre 2022]. Disponible en: https://apps.who.int/iris/bitstream/handle/10665/336656/9789240015128-eng.pdf
Marques Santana G. Evaluación de la efectividad de una intervención basada en la gestión de la farmacoterapia asociada a la educación terapéutica en pacientes de riesgo cardiovascular (Tesis Doctoral). Sevilla: Universidad de Sevilla; 2011. 195 p.
Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67-74.
Asociación Médica Mundial (AMM). Declaración de Helsinki. Investigación médica en seres humanos [Internet]. 2022 Noviembre [citado 26 Noviembre 2022]. (version 2013). Diponible en: https://www.wma.net/es/que-hacemos/etica-medica/declaracion-de-helsinki/
Ogunsina K, Dibaba DT, Akinyemiju T. Association between life-course socio-economic status and prevalence of cardio-metabolic risk factors in five middle-income countries. J GlobHealth. 2018;8(2):020405.
Van Stappen V, Latomme J, Cardon G, De Bourdeaudhuij I, Lateva M, Chakarova N, et al. On behalf of the Feel4Diabetes-Study Group. Barriers from Multiple Perspectives Towards Physical Activity, Sedentary Behaviour, Physical Activity and Dietary Habits When Living in Low Socio-Economic Areas in Europe. The Feel4Diabetes Study. Int J Environ Res PublicHealth. 2018;15:2840.
Newton S, Braithwaite D, Akinyemiju TF. Socio-economic status over the life course and obesity: Systemic review and mea-analysis. PLoSOne. 2017;12(5): e0177151.
Silverman MG, Ference BA, Kyungah IM, Wiviott SD, Giugliano RP, Grundy SM, et al. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions. A Systematic Review and Meta-analysis. JAMA. 2016;316(12):1289-1297.
SenS, Chakraborty R. Treatment and Diagnosis of Diabetes Mellitus and Its Complication: Advanced Approaches. Mini RevMedChem. 2015;15(14):1132-3. DOI: 10.2174/138955751514151006154616.
Eid S, Sas KM, Abcouwer SF , Feldman EL, Gardner TW, Pennathur S, et al. New insights into the mechanisms of diabetic complications: role of lipids and lipidmetabolism.Diabetologia. 2019;62(9):1539-49. DOI: 10.1007/s00125-019-4959-1. Epub 2019 Jul 25.
Kuntz B, Lampert T. Socioeconomic factors and obesity. DtschArzteblInt. 2010;107(30):517-522.
Allagbé I, Zeller M, Thomas D, Airagnes G, Limosin F, Boussadi A, et al. Cardiovascular Risk Among Patients Who Smoke: Risk Profiles and Differences by Sex. Am J Prev Med. 2022;63(5):800-8. DOI: 10.1016/j.amepre.2022.04.028. Epub 2022 Jun 27. PMID: 35773102.
Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA. 2003;290:86–97.
Cuevas Fernández FJ, Iglesias Girón MJ, Rodríguez Pérez MC, Ortiz Simarro S, Cabrera de León A, Aguirre-Jaime A. Evolución del tabaquismo según clase social en la población adulta de las Islas Canarias durante el periodo 2000-2015: seguimiento de la cohorte CDC-Canarias. Aten Primaria. 2020;52(6):381-388. doi:10.1016/j.aprim.2019.05.007
SEFAC.Una de cada cuatro personas que quiere dejar de fumar recurre al farmacéutico en su primer intento. [Internet]. 2019 Noviembre. [citado el 20 de Noviembre de 2022]. Disponible en: https://www.sefac.org/notas-de-prensa/el-25-de-fumadores-recurre-al-farmaceutico-en-su-1o-intento-de-cesacion.
Bofí Martínez P, GarcíaJiménez E, MartínezMartínez F. Comparison of health education and drug therapy monitoring interventions in patients with cardiovascular risk factors attending a community pharmacy (FISFTES-PM Study). Aten primaria. 2015;47(3):141-148.
Tsuyuki RT, Al Hamarneh YN, Jones CA, Hemmelgarn BR. The Effectiveness of Pharmacist Interventions on Cardiovascular Risk: the Multicenter Randomized Controlled RxEACH Trial. J Am CollCardiol. 2016;67(24):2846-2854.
Artés M, Martin Oliveros A, Iracheta Todó M, de Diego Colilla V, Gil Sánez E, Catalá Cerdan A, et al. Clinical impact of a pharmaceutical profesional service intervention with or without a multi- compartment medication in non-adherent, uncontrolled, chronic hypertensive, polymedicated patients in spanish community pharmacies. SEFAC-SPD- VALOR STUDY. 2018;21(supl.3): S270- S271.
Filié Haddad M, SatieTakamiya A, Martins da Silva EM, Barros Barbosa D. Farmacología en la tercera edad: medicamentos de uso continuo y peligros de la interacción medicamentosa. Gerokomos. 2009;20(1).
Carrera-Lasfuentes P, Aguilar-Palacio I, Clemente Roldán E, Malo Fumanal S, RabanaqueHernández MK. Consumo de medicamentos en población adulta: influencia del autoconsumo. Aten Primaria. 2013;45(10):429-535.
Rodríguez Chamorro MA, García-Jiménez E, Amariles P, Rodríguez Chamorro A, Pérez Merino EM, MartínezMartínez E, et al. Efecto de la actuaciónfarmacéutica en la adherencia del tratamiento farmacológico de pacientes ambulatorios con riesgo cardiovascular (EMDader-CV- Incumplimiento). Universidad de Granada. Aten Primaria. 2011;43(5):245-253.
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Rocío De la Puerta Vázquez
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:
- The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.
b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.
c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).
